Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Bought by State Street Corp

State Street Corp grew its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 101.4% during the third quarter, HoldingsChannel reports. The firm owned 821,131 shares of the company’s stock after purchasing an additional 413,425 shares during the quarter. State Street Corp’s holdings in Dianthus Therapeutics were worth $22,483,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Janus Henderson Group PLC grew its holdings in Dianthus Therapeutics by 40.5% in the third quarter. Janus Henderson Group PLC now owns 949,334 shares of the company’s stock valued at $25,936,000 after purchasing an additional 273,670 shares during the period. Great Point Partners LLC boosted its holdings in shares of Dianthus Therapeutics by 21.3% in the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock valued at $19,615,000 after purchasing an additional 132,929 shares during the last quarter. Braidwell LP grew its stake in shares of Dianthus Therapeutics by 34.6% during the 3rd quarter. Braidwell LP now owns 493,687 shares of the company’s stock valued at $13,517,000 after buying an additional 126,836 shares during the period. Point72 Asset Management L.P. grew its stake in shares of Dianthus Therapeutics by 151.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock valued at $11,984,000 after buying an additional 263,500 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Dianthus Therapeutics by 142.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock worth $4,543,000 after buying an additional 97,362 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Analyst Upgrades and Downgrades

DNTH has been the subject of several research analyst reports. Oppenheimer upped their price target on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Finally, TD Cowen initiated coverage on shares of Dianthus Therapeutics in a research report on Friday. They issued a “buy” rating for the company. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $46.43.

Dianthus Therapeutics Stock Up 3.3 %

DNTH opened at $23.80 on Monday. The firm has a market capitalization of $704.48 million, a P/E ratio of -9.52 and a beta of 1.74. The firm’s 50 day moving average is $25.69 and its 200-day moving average is $26.64. Dianthus Therapeutics, Inc. has a 52-week low of $7.75 and a 52-week high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $1.07 million. Equities analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.